2025. 02
Date： 2025.02.12 -
Caliway Biopharmaceuticals Added to MSCI World Small Cap Index, Reinforcing Global Standing
New Taipei City, February 12, 2025 – Caliway Biopharmaceuticals (TWSE: 6919) has been added to the MSCI World Small Cap Index, as announced today by MSCI (Morgan Stanley Capital International) in its latest quarterly review. The inclusion will take effect after the market close on February 27.
This sets a record as the fastest inclusion of a Taiwanese biotech company in the MSCI Index post-listing, achieving a key 2025 operational milestone ahead of schedule. Since its IPO in October 2024, Caliway has surpassed USD 4 billion in market capitalization, securing its place among Taiwan’s top 100 enterprises and demonstrating strong growth momentum and competitiveness.
The MSCI indices are among the world’s most influential benchmarks, tracking high-quality companies that meet strict criteria for market capitalization, liquidity, and financial strength. Changes in index constituents impact global capital flows and serve as key indicators of a company’s international competitiveness and market value.
For Caliway, this recognition affirms its solid operational performance and long-term growth potential. The inclusion further strengthens its presence in the global biopharmaceutical sector, supporting future international clinical advancement and commercialization.
Caliway continues to focus on advancing CBL-514’s global clinical development, expanding international partnerships, and driving forward its vision of "Market Changer Innovation." The company continues to create long-term value for the healthcare industry, investors, and patients worldwide.
This sets a record as the fastest inclusion of a Taiwanese biotech company in the MSCI Index post-listing, achieving a key 2025 operational milestone ahead of schedule. Since its IPO in October 2024, Caliway has surpassed USD 4 billion in market capitalization, securing its place among Taiwan’s top 100 enterprises and demonstrating strong growth momentum and competitiveness.
The MSCI indices are among the world’s most influential benchmarks, tracking high-quality companies that meet strict criteria for market capitalization, liquidity, and financial strength. Changes in index constituents impact global capital flows and serve as key indicators of a company’s international competitiveness and market value.
For Caliway, this recognition affirms its solid operational performance and long-term growth potential. The inclusion further strengthens its presence in the global biopharmaceutical sector, supporting future international clinical advancement and commercialization.
Caliway continues to focus on advancing CBL-514’s global clinical development, expanding international partnerships, and driving forward its vision of "Market Changer Innovation." The company continues to create long-term value for the healthcare industry, investors, and patients worldwide.